Calidi Biotherapeutics, Inc. CLDI · Stock Open Calidi Biotherapeutics, Inc. in new tab
Calidi Biotherapeutics, Inc. Analysis (CLDI)
Is Calidi Biotherapeutics, Inc. a good investment? Calidi Biotherapeutics, Inc. (CLDI) is currently trading at 0.6499 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.75. This relatively low multiple may signal that Calidi Biotherapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Calidi Biotherapeutics, Inc. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.90.
Investor FAQ
Does Calidi Biotherapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Calidi Biotherapeutics, Inc.?
Calidi Biotherapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -36.47.
Company Profile
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Split Date | Split Ratio to 1 |
|---|---|
| July 15, 2024 | 1:10 |
| Aug. 5, 2025 | 0.08 |
Community Discussion